Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-finding study of BMF-219 in relapsed or refractory hematologic malignancies
NL-OMON59256Phase 1Completed
- Sponsor
- Biomea Fusion
- Start
- May 2023
- Modality
- Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icovamenib in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL) and 2 more, sponsored by Biomea Fusion. Primary endpoint: Primary endpoint(s). Started May 2023; status: completed.
02
Drugs
icovamenib
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON59256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59256.